https://bioinformatics.umg.eu/onkopus/drugon#antineoplasticimmunecheckpointinhibitor
Properties
- label
- [] antineoplastic--immune checkpoint inhibitor
Parents
Children
Relations
- is_kegg_class
- atezolizumab
- is_kegg_group
- favezelimab
- is_kegg_group
- ieramilimab
- is_kegg_class
- nivolumab
- is_kegg_group
- vudalimab
- is_kegg_group
- etigilimab
- is_kegg_class
- pembrolizumab
- is_kegg_group
- cetrelimab
- is_kegg_group
- cemiplimab
- is_kegg_group
- retifanlimab
- is_kegg_group
- ipilimumab
- is_kegg_group
- balstilimab
- is_kegg_group
- tuparstobart
- is_kegg_class
- durvalumab
- is_kegg_class
- avelumab
- is_kegg_group
- pacmilimab
- is_kegg_group
- tiragolumab
- is_kegg_group
- domvanalimab
- is_kegg_group
- pidilizumab
- is_kegg_group
- zeluvalimab
- is_kegg_group
- tremelimumab
- is_kegg_group
- volrustomig
- is_kegg_group
- nivolumabandrelatlimab
- is_kegg_group
- izuralimab
- is_kegg_group
- pimivalimab
- is_kegg_group
- relatlimab
- is_kegg_class
- cemiplimab
- is_kegg_group
- quavonlimab
- is_kegg_group
- botensilimab
- is_kegg_group
- budigalimab
- is_kegg_group
- atezolizumab
- is_kegg_class
- ipilimumab
- is_kegg_group
- lodapolimab
- is_kegg_group
- ociperlimab
- is_kegg_group
- danburstotug
- is_kegg_group
- dostarlimab
- is_kegg_group
- cadonilimab
- is_kegg_class
- retifanlimab
- is_kegg_group
- durvalumab
- is_kegg_group
- inbakicept
- is_kegg_group
- tislelizumab
- is_kegg_group
- sintilimab
- is_kegg_group
- belrestotug
- is_kegg_group
- bavunalimab
- is_kegg_class
- nivolumabandrelatlimab
- is_kegg_group
- zalifrelimab
- is_kegg_group
- pembrolizumab
- is_kegg_group
- enristomig
- is_kegg_group
- bintrafuspalfa
- is_kegg_group
- zimberelimab
- is_kegg_group
- spartalizumab
- is_kegg_group
- avelumab
- is_kegg_group
- nivolumab
- is_kegg_group
- penpulimab
- is_kegg_group
- cosibelimab
- is_kegg_group
- toripalimab
- is_kegg_class
- dostarlimab
- is_kegg_group
- vibostolimab
- is_kegg_class
- tremelimumab